021-51111890
购物车（）
sales@molnova.cn
AT-533
CAS No. 908112-37-8
AT-533 ( —— )
产品货号. M36016 CAS No. 908112-37-8
AT-533 是一种有效的 Hsp90 和 HSV 抑制剂。AT-533 通过阻断 HIF-1α/VEGF/VEGFR-2 信号通路抑制肿瘤生长和血管生成。AT-533 还抑制下游通路的激活，包括 Akt/mTOR/p70S6K, Erk1/2 和 FAK。AT-533 抑制人脐静脉内皮细胞 (HUVEC) 的管形成、细胞迁移和侵袭。
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 5MG | ￥744 | 有现货 |
|
| 10MG | ￥1169 | 有现货 |
|
| 25MG | ￥2139 | 有现货 |
|
| 50MG | ￥3190 | 有现货 |
|
| 100MG | ￥4077 | 有现货 |
|
| 200MG | ￥5499 | 有现货 |
|
| 500MG | 获取报价 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
| 1 mL x 10 mM in DMSO | ￥785 | 有现货 |
|
生物学信息
-
产品名称AT-533
-
注意事项本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断
-
产品简述AT-533 是一种有效的 Hsp90 和 HSV 抑制剂。AT-533 通过阻断 HIF-1α/VEGF/VEGFR-2 信号通路抑制肿瘤生长和血管生成。AT-533 还抑制下游通路的激活，包括 Akt/mTOR/p70S6K, Erk1/2 和 FAK。AT-533 抑制人脐静脉内皮细胞 (HUVEC) 的管形成、细胞迁移和侵袭。
-
产品描述AT-533 is a potent Hsp90 and HSV inhibitor. AT-533 suppresses tumor growth and angiogenesis by blocking the HIF-1α/VEGF/VEGFR-2 signaling pathway. AT-533 also inhibits the activation of the downstream pathways, including Akt/mTOR/p70S6K, Erk1/2 and FAK. AT-533 inhibits the tube formation, cell migration, and invasion of human umbilical vein endothelial cells (HUVECs).
-
体外实验Cell Viability Assay Cell Line:Human umbilical vein endothelial cells (HUVECs): MCF-7 and MDA-MB-231 Concentration:0, 5.6, 16.7, 50, 150, 450, and 1350 nM Incubation Time:12 h, 24 h, 48 h, and 72 h Result:Inhibited cell viability at 48 h with an IC50 value of 50.1 nM. Western Blot Analysis Cell Line:MCF-7 cells and MDA-MB-231 cells Concentration:5 nM, 10 nM, 50 nM, and 75 nM Incubation Time:24 h Result:Inhibited the phosphorylation of VEGF-2, Akt, mTOR, Erk1/2, FAK.
-
体内实验Animal Model:Male C57BL/6 mice with MDA-MB-231 breast cancer xenografts Dosage:10 mg/kg;Administration:Intraperitoneal injection; once daily for 21 days Result:Significantly downregulated HIF-1α and VEGF expression.
-
同义词——
-
通路Cytoskeleton/Cell Adhesion Molecules
-
靶点HSP
-
受体HSP | HSV
-
研究领域——
-
适应症——
化学信息
-
CAS Number908112-37-8
-
分子量410.51
-
分子式C23H30N4O3
-
纯度>98% (HPLC)
-
溶解度In Vitro:?DMSO 中的溶解度 : 33.33 mg/mL (81.19 mM; 超声助溶 (<60°C)
-
SMILESCc1nn(c2CC(C)(C)CC(=O)c12)-c1ccc(C(N)=O)c(N[C@H]2CC[C@H](O)CC2)c1
-
化学全称——
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Zhang PC, et al. AT-533, a novel Hsp90 inhibitor, inhibits breast cancer growth and HIF-1α/VEGF/VEGFR-2-mediated angiogenesis in vitro and in vivo. Biochem Pharmacol. 2020 Feb;172:113771. ?
产品手册
关联产品
-
PU-H71 HCl
PU-H71 HCl (Zelavespib HCl) is a novel Hsp90 inhibitor, a novel purine-based analog, and a radiosensitizer that may be a promising agent for CIRT. PU-H71 HCL shows antitumor activity in many preclinical models of malignancy. PU-H71 HCL has an inhibitory effect on the protein expression levels of Rad51 and Ku70, which may be associated with the double chain break repair in the homologous recombination pathway and non-homologous end-joining pathway.
-
17-AAG hydrochloride
一种有效的 Hsp90 抑制剂，在无细胞测定中 IC50 为 5 nM。
-
KUNG29
一种有效的选择性 Grp94 抑制剂，Kd 为 0.2 uM。
